News Agency
The Times

Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

  • Written by Media Outreach
  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks
  • UBT251...

Read more: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

How Does Temporary Fencing Help Simplify Project Planning?

Why Does Temporary Fencing Matter During Project Planning?  A controlled boundary is essential when construction, infrastructure maintenance, demolition,  landscaping, and other projects are underway. That is when temporary fencing becomes an important  option to consider. The fencing layout affects more than site... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion